Successes and challenges of leukaemia treatment using CAR-T cells – where are we now?

Treatment of leukaemia and lymphomas using genetically modified immune cells of the patient (CAR-T cells) has produced impressive results in clinical trials, especially for the treatment of B-cell malignancies. However, serious adverse events were reported as well, partly with fatal outcome. A detailed summary of previously published results and a discussion of the reasons why less than ten percent of the clinical trials are conducted in Europe have been published by researchers under the supervision of the Paul-Ehrlich-Insitute in EMBO Molecular Medicine (01 August 2017, online early view). (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)